Symptomatisch perifeer arterieel vaatlijden

Bronnen

1. Wees PJ van der, Hendriks HJM, Heldoorn M, Custers JWH, Bie RA de. Methode voor ontwikkeling, implementatie en bijstelling van KNGF-richtlijnen. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2007.

2. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-906.

3. Bartelink ML, Stoffers HEJH, Boutens EJ, Hooi JD, Kaiser V, Boomsma LJ. NHG-Standaard Perifeer arterieel vaatlijden. Huisarts Wet 2003;46(14):848-58.

4. CBO. Handleiding voor werkgroepleden. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO; 2007.

5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67.

6. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185-91.

7. Kroger K, Stang A, Kondratieva J, Moebus S, Beck E, Schmermund A, et al. Prevalence of peripheral arterial disease – results of the Heinz Nixdorf recall study. Eur J Epidemiol. 2006;21(4):279-85.

8. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366(9499):1773-83.

9. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-43.

10. Rutgers D, Meijer WT, Hoes AW, Bots ML, Hofman A, Grobbee DE. Prevalentie van perifere arteriële vaatziekte en PAV bij personen van 55 jaar en ouder: het ERGO-onderzoek. Ned Tijdschr Geneeskd. 1998;142(52):2851-6.

11. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000;160(19):2934-8.

12. Vaartjes I, Dis I van, Visseren FLJ, Bots ML. Hart- en vaatziekten in Nederland bij vrouwen en mannen. In: Vaartjes I, Dis I van, Visseren FLJ, Bots ML, editors. Hart- en vaatziekten in Nederland 2011, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Hartstichting; 2011.

13. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317-24.

14. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985;33(1):13-8.

15. Hooi JD, Kester AD, Stoffers HE, Overdijk MM, Ree JW van, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol. 2001;153(7):666-72.

16. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord. 2005;5:14.

17. Kugler C, Rudofsky G. The role of comorbidity burden for patients with symptomatic peripheral arterial disease (PAD). A quantitative approach. Int Angiol. 2003;22(3):290-301.

18. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172-81.

19. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109(6):733-9.

20. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-6.

21. Siracuse JJ, Giles KA, Pomposelli FB, Hamdan AD, Wyers MC, Chaikof EL, et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012;55(4):1001-7.

22. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347(24):1941-51.

23. Nordanstig J, Smidfelt K, Langenskiold M, Kragsterman B. Nationwide experience of cardio- and cerebrovascular complications during infrainguinal endovascular intervention for peripheral arterial disease and acute limb ischaemia. Eur J Vasc Endovasc Surg. 2013;45(3):270-4.

24. Beers MH, Berga SL, Batterink J. Merck Manual Medisch Handboek. Houten: Bohn Stafleu van Loghum; 2005.

25. Bernards JA, Bouwman LN. Fysiologie van de mens. Utrecht: Bohn Scheltema en Holkema; 1994.

26. McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med. 2006;73 Suppl 4:S2-7.

27. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. JAAC. 2006;47(6):1239-312.

28. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292(4):453-61.

29. Cox GS, Hertzer NR, Young JR, O’Hara PJ, Krajewski LP, Piedmonte MR, et al. Nonoperative treatment of superficial femoral artery disease: long-term follow-up. J Vasc Surg. 1993;17(1):172-81; discussion 81-2.

30. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12(2):123-37.

31. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg. 2001;34(6):962-70.

32. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3(2):229-34.

33. Muir RL. Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention. J Vasc Nurs. 2009;27(2):26-30.

34. Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther. 2006;13 Suppl 2:II3-9.

35. Ouriel K. Peripheral arterial disease. Lancet. 2001;358(9289):1257-64.

36. Hildebrandt VH, Chorus AMJ, Stubbe JH. Trendrapport Bewegen en Gezondheid 2008/2009. TNO Kwaliteit van Leven. Leiden: De Bink; 2010.

37. Hooi JD, Stoffers HE, Knottnerus JA, Ree JW van. The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence. Br J Gen Pract. 1999;49(438):49-55.

38. Nicoloff AD, Taylor LM, Jr., Sexton GJ, Schuff RA, Edwards JM, Yeager RA, et al. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg. 2002;35(1):38-46; discussion 46-7.

39. Romero JM, Bover J, Fite J, Bellmunt S, Dilme JF, Camacho M, et al. The Modification of Diet in Renal Disease 4-calculated glomerular filtration rate is a better prognostic factor of cardiovascular events than classical cardiovascular risk factors in patients with peripheral arterial disease. J Vasc Surg. 2012 Nov 56(5):1324-30.

40. Hooi JD, Stoffers HE, Kester AD, Ree JW van, Knottnerus JA. Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle-brachial pressure index. Med Decis Making. 2002;22(2):99-107.

41. Haugen S, Casserly IP, Regensteiner JG, Hiatt WR. Risk assessment in the patient with established peripheral arterial disease. Vasc Med. 2007;12(4):343-50.

42. Goessens BM, Graaf Y van der, Olijhoek JK, Visseren FL. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2007;45(1):47-54.

43. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009;23(5):690-9.

44. Heerkens YF, Hendriks HJM, Graaf-Peters VB de. KNGF-richtlijn Fysiotherapeutische verslaglegging. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2011.

45. Achttien RJ, Staal JB, Merry AHH, Voort SSEM van der, Klaver RJ, Schoonewille S, et al. KNGF-richtlijn Hartrevalidatie. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2011.

46. Jongert MWA, Hendriks HJM, Hoek J van, Klaasboer-Kogelman K, Robeer GG, Simens B, et al. KNGF-richtlijn Claudicatio Intermittens. Ned Tijdschr Fysiother. 2003;6.

47. Kruidenier LM, Nicolai SP, Willigendael EM, Bie RA de, Prins MH, Teijink JA. Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication. BMC Cardiovasc Disord. 2009;9:9.

48. Zwierska I, Nawaz S, Walker RD, Wood RF, Pockley AG, Saxton JM. Treadmill versus shuttle walk tests of walking ability in intermittent claudication. Med Sci Sports Exerc. 2004;36(11):1835-40.

49. Womack CJ, Gardner AW. Peripheral Arterial Disease. In: Durstine JL, Moore GE, editors. ACSM’s Exercise Management for Persons with Chronic Diseases and Disabilities. Champaign: Human Kinetics; 2003. p. 81-5.

50. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23(4):402-8.

51. Nicolai SP, Viechtbauer W, Kruidenier LM, Candel MJ, Prins MH, Teijink JA. Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. J Vasc Surg. 2009;50(2):322-9.

52. Revalidatiecommissie NVVC / NHS en projectgroep PAAHR. Multidisciplinaire Richtlijn Hartrevalidatie 2011. Utrecht: Nederlandse Vereniging Voor Cardiologie; 2011.

53. Kemper HGC, Ooijendijk WTM, Stiggelbout M. Consensus over de Nederlandse norm voor gezond bewegen. Tijdschr Soc Gezondheidsz. 2000;78(3):180-3.

54. Ades PA, Savage PD, Toth MJ, Harvey-Berino J, Schneider DJ, Bunn JY, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation. 2009;119(20):2671-8.

55. Celis R, Pipinos, II, Scott-Pandorf MM, Myers SA, Stergiou N, Johanning JM. Peripheral arterial disease affects kinematics during walking. J Vasc Surg. 2009;49(1):127-32.

56. Chen SJ, Pipinos I, Johanning J, Radovic M, Huisinga JM, Myers SA, et al. Bilateral claudication results in alterations in the gait biomechanics at the hip and ankle joints. J Biomech. 2008;41(11):2506-14.

57. Crowther RG, Spinks WL, Leicht AS, Quigley F, Golledge J. Relationship between temporal-spatial gait parameters, gait kinematics, walking performance, exercise capacity, and physical activity level in peripheral arterial disease. J Vasc Surg. 2007;45(6):1172-8.

58. Koutakis P, Johanning JM, Haynatzki GR, Myers SA, Stergiou N, Longo GM, et al. Abnormal joint powers before and after the onset of claudication symptoms. J Vasc Surg. 2010;52(2):340-7.

59. Koutakis P, Pipinos, II, Myers SA, Stergiou N, Lynch TG, Johanning JM. Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral claudication. J Vasc Surg. 2010;51(1):80-8.

60. Wurdeman SR, Koutakis P, Myers SA, Johanning JM, Pipinos, II, Stergiou N. Patients with peripheral arterial disease exhibit reduced joint powers compared to velocity-matched controls. Gait Posture. 2012;36(3):506-9.

61. Brunnekreef JJ, Uden CJ van, Moorsel S van, Kooloos JG. Reliability of videotaped observational gait analysis in patients with orthopedic impairments. BMC Musculoskelet Disord. 2005;6:17.

62. Dros J, Wewerinke A, Bindels PJ, Weert HC van. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Ann Fam Med. 2009;7(6):555-8.

63. Mens JMA, Chavannes AW, Koes BW, Lubbers WJ, Ostelo RWJG, Spinnewijn WEM, et al. NHG-Standaard Lumbosacraal radiculair syndroom (Eerste herziening). Huisarts Wet. 2005;48(4):171-8.

64. Nugteren K van. 4a Addendum: kanaalstenose van de limbale wervelkolom. In: van Nugteren K, Winkel D, editors. Onderzoek en behandeling van lage rugklachten. Houten: Bohn Stafleu van Loghum; 2006. p. 101-2.

65. Bravenboer B, Dam PS van, Biessels GJ, Gispen WH. Richtlijn diabetische neuropathie. Amersfoort: Nederlandse Diabetes Federatie; 2003.

66. Peter WFH, Jansen MJ, Bloo H, Dekker-Bakker LMMCJ, Dilling RG, Hilberdink WKHA, et al. KNGF-richtlijn Artrose heup-knie. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2010.

67. Hoogeveen AR. Richtlijn Chronisch compartimentsyndroom van het onderbeen. Bilthoven: Vereniging voor Sportgeneeskunde; 2010.

68. Belo JN, Bierma-Zeinstra SM, Raaijmakers AJ, Wissel F van der, Opstelten W. NHG-Standaard Niet-traumatische knieproblemen bij volwassenen. Huisarts Wet. 2008;51(5):229-40.

69. Praet SFE, Uden C van, Hartgens F, Savelberg HHCM, Toereppel K, Bie RA de. KNGF-Standaard Beweeginterventie diabetes mellitus type 2. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2009.

70. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-76.

71. Gosselink R, Langer D, Burtin C, Probst V, Hendriks HJM, Schans CP van der, et al. KNGF-richtlijn Chronisch obstructieve longziekten. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2008.

72. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, Domburg RT van, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. JACC. 2008;51(16):1588-96.

73. Kemp K von, Brande P van den, Peterson T, Waegeneers S, Scheerlinck T, Danau W, et al. Screening for concomitant diseases in peripheral vascular patients. Results of a systematic approach. Int Angiol. 1997;16(2):114-22.

74. Rutten FH, Bohnen AM, Schreuder BP, Pupping MDA, Bouma M. NHG-Standaard Stabiele angina pectoris. Huisarts Wet. 2004;47(2):83-95.

75. Verhoeven S, Beusmans GHMI, Bentum STB van, Binsbergen JJ van, Pleumeekers HJCM, Schulling J, et al. NHG-Standaard CVA. Huisarts Wet. 2004;47(101):509-20.

76. Peppen RPS van, Kwakkel G, Harmeling-van der Wel BC, Kollen BJ, Hobbelen JSM, Buurke JH, et al. KNGF-richtlijn Beroerte. Amersfoort: Koninklijk Nederlands Genootschap voor Fysiotherapie; 2004.

77. McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women’s health and aging study. Circulation. 2000;101(9):1007-12.

78. Kortleve V. Shared decision-making. FysioPraxis. 2012;7:22-4.

79. Burgt M van der, Verhulst F. Doen en blijven doen. Houten: Bohn Stafleu van Loghum; 2009.

80. Dijkstra A. Het veranderingsmodel als leidraad bij het motiveren tot en begeleiden van gedragsverandering bij patiënten. Ned Tijdschr Fysiother. 2002;112(3):62-8.

81. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008(4):CD000990.

82. Stewart AH, Lamont PM. Exercise training for claudication. Surgeon. 2007;5(5):291-9.

83. Wind J, Koelemay MJ. Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials. Eur J Vasc Endovasc Surg. 2007;34(1):1-9.

84. Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MG, Rouwet EV, et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg. 2012;56(4):1132-42.

85. Robeer GG, Brandsma JW, van den Heuvel SP, Smit B, Oostendorp RA, Wittens CH. Exercise therapy for intermittent claudication: a review of the quality of randomised clinical trials and evaluation of predictive factors. Eur J Vasc Endovasc Surg. 1998;15(1):36-43.

86. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274(12):975-80.

87. Kruidenier LM, Viechtbauer W, Nicolai SP, Buller H, Prins MH, Teijink JA. Treatment for intermittent claudication and the effects on walking distance and quality of life. Vascular. 2012;20(1):20-35.

88. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006(2):CD005263.

89. Lundgren F, Dahllof AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication – surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg. 1989;209(3):346-55.

90. Gelin J, Jivegard L, Taft C, Karlsson J, Sullivan M, Dahllof AG, et al. Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no treatment in unselected randomised patients I: one year results of functional and physiological improvements. Eur J Vasc Endovasc Surg. 2001;22(2):107-13.

91. Frans FA, Bipat S, Reekers JA, Legemate DA, Koelemay MJ. Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg. 2012;99(1):16-28.

92. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130-9.

93. Womack CJ, Sieminski DJ, Katzel LI, Yataco A, Gardner AW. Improved walking economy in patients with peripheral arterial occlusive disease. Med Sci Sports Exerc. 1997;29(10):1286-90.

94. Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011;123(1):87-97.

95. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. Eur J Cardiovasc Prev Rehabil. 2010;17(2):140-54.

96. Spronk S, Bosch JL, Veen HF, Hoed PT den, Hunink MG. Intermittent claudication: functional capacity and quality of life after exercise training or percutaneous transluminal angioplasty – systematic review. Radiology. 2005;235(3):833-42.

97. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. Sports Med. 2004;34(14):983-1003.

98. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: Walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis. 2011;218(1):1-12.

99. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg. 2012;55(5):1346-54.

100. Gardner AW, Montgomery PS, Flinn WR, Katzel LI. The effect of exercise intensity on the response to exercise rehabilitation in patients with intermittent claudication. J Vasc Surg. 2005;42(4):702-9.

101. Nicolai SP, Teijink JA, Prins MH. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg. 2010;52(2):348-55.

102. Bendermacher BL, Kruidenier LM, Nicolai SP, Welten RJ, Teijink JA. Supervised exercise therapy for intermittent claudication. Acta Chir Belg. 2007;107(6):616-22.

103. Wenkstetten-Holub A, Kandioler-Honetz E, Kraus I, Muller R, Kurz RW. [Effect of supervised exercise training on walking speed, claudication distance and quality of life in peripheral arterial disease]. Wien Med Wochenschr. 2012;162(15-16):330-6.

104. Collins TC, Lunos S, Carlson T, Henderson K, Lightbourne M, Nelson B, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. Diabetes Care. 2011;34(10):2174-9.

105. King S, Vanicek N, Mockford KA, Coughlin PA. The effect of a 3-month supervised exercise programme on gait parameters of patients with peripheral arterial disease and intermittent claudication. Clin Biomech (Bristol, Avon). 2012 Oct;27(8):845-51.

106. Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J. The influence of a long term exercise program on lower limb movement variability and walking performance in patients with peripheral arterial disease. Hum Mov Sci. 2009;28(4):494-503.

107. Crowther RG, Spinks WL, Leicht AS, Sangla K, Quigley F, Golledge J. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease. J Vasc Surg. 2008;47(2):303-9.

108. Izquierdo-Porrera AM, Gardner AW, Powell CC, Katzel LI. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. J Vasc Surg. 2000;31(4):670-7.

109. Barak S, Stopka CB, Archer Martinez C, Carmeli E. Benefits of low-intensity pain-free treadmill exercise on functional capacity of individuals presenting with intermittent claudication due to peripheral arterial disease. Angiology. 2009;60(4):477-86.

110. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997;48(4):291-300.

111. Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc Med. 1997;2(3):238-42.

112. Laukkanen JA, Kurl S, Salonen R, Rauramaa R, Salonen JT. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study. Eur Heart J. 2004;25(16):1428-37.

113. Morree JJ de, Jongert MWA, Poel G van der. Inspanningsfysiologie, oefentherapie en training. Tweede, herziene druk ed. Houten: Bohn Stafleu van Loghum; 2011.

114. McArdle WD, Katch FI, Katch VL. Exercise Physiology: Energy, Nutrition, and Human Performance. 7th edition ed. Philadelphia: Lippincott Williams & Wilkins; 2009.

115. Jongert T, Benedictus J, Dijkgraaf J, Koers H, Oudhof J. Het gebruik van de Borgschaal bij bewegingsactiviteiten voor hartpatiënten. Maarssen: Elsevier Gezondheidszorg, Hart in Beweging; 2004.

116. Lauret GJ, Dalen HC van, Hendriks HJ, Sterkenburg SM van, Koelemay MJ, Zeebregts CJ, et al. When is supervised exercise therapy considered useful in peripheral arterial occlusive disease? A nationwide survey among vascular surgeons. Eur J Vasc Endovasc Surg. 2012;43(3):308-12.

117. Gardner AW, Killewich LA, Montgomery PS, Katzel LI. Response to exercise rehabilitation in smoking and nonsmoking patients with intermittent claudication. J Vasc Surg. 2004;39(3):531-8.

118. Fritschi C, Collins EG, O’Connell S, McBurney C, Butler J, Edwards L. The Effects of Smoking Status on Walking Ability and Health-Related Quality of Life in Patients With Peripheral Arterial Disease. J Cardiovasc Nurs. 2012. Jul-Aug;28(4):380-6.

119. Platform Vitale Vaten. Zorgstandaard Cardiovasculair Risicomanagement 2013. Den Haag: 2013.

120. Banga JD, Dijk JL van, Dis I van, Giepmans L, Goudswaard AN, Grobbee DE, et al. NHG-Standaard Cardiovasculair Risicomanagement (eerste herziening). Huisarts Wet. 2012;55(1):14-28.

121. Hendriks HJM, Ettekoven H van, Reitsma E, Verhoeven ALJ, Wees J van der. Methode voor centrale richtlijnontwikkeling en implementatie in de fysiotherapie. Amersfoort: KNGF/NPi/CBO; 1998.